Related Experiment Video
Updated: Jun 8, 2026
08:41
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Paclitaxel-coated balloons - Survey of preclinical data
B Schnorr1, B Kelsch, B Cremers
1Department of Radiology, Experimental Radiology, Charité, University Hospital, Berlin, Germany. beatrix.schnorr@charite.de
Minerva Cardioangiologica
|October 16, 2010
Summary
Drug-coated balloons offer a stent-free option to prevent artery restenosis. Paclitaxel-coated balloons show promise in reducing restenosis rates after angioplasty.
Area of Science:
- Cardiovascular medicine
- Biomaterials science
- Interventional cardiology
Background:
- Restenosis, the re-narrowing of arteries after intervention, is a significant clinical challenge.
- Drug-eluting stents have reduced restenosis rates in coronary arteries.
- Non-stent-based local drug delivery methods offer repeatable, non-permanent solutions for restenosis inhibition.
Purpose of the Study:
- To review the development and effectiveness of paclitaxel-coated angioplasty balloons for restenosis prevention.
- To provide an overview of preclinical and clinical data for paclitaxel-coated balloons.
- To discuss factors influencing the efficacy and safety of drug-coated balloons.
Main Methods:
- Review of preclinical studies on paclitaxel-coated balloons.
- Analysis of clinical trial outcomes comparing drug-coated balloons to other interventions.
- Evaluation of formulation and coating techniques for drug-coated balloons.
Main Results:
- Paclitaxel embedded in balloon coatings effectively inhibits restenosis by inhibiting cell proliferation.
- Clinical studies demonstrate reduced late lumen loss and lower restenosis rates with paclitaxel-coated balloons.
- Formulation and coating technology are critical for the safety and effectiveness of drug-coated balloons.
Conclusions:
- Paclitaxel-coated angioplasty balloons are an effective non-stent-based strategy for preventing arterial restenosis.
- Further research and development, including exploration of agents like zotarolimus, continue to advance this field.
- Optimizing drug formulation and coating is essential for maximizing the benefits of drug-coated balloons.
